Table 1 Demographic, plasma YKL-40 concentrations and diagnostic accuracy in discrimination from healthy controls and neurological disease groups
From: Plasma YKL-40 in the spectrum of neurodegenerative dementia
n | Sex (f/m) | Age (years) | YKL-40 (ng/mL) | AUC (95% CI) | |||
|---|---|---|---|---|---|---|---|
Mean + SD | 95% CI | vs. HC | vs. ND | ||||
HC | 70 | 22/48 | 66 ± 5 | 84 ± 84 | 63–104 | 0.64 (0.53–0.74) | |
ND | 44 | 26/18 | 66 ± 12 | 95 ± 61 | 76–114 | 0.64 (0.53–0.74) | |
AD | 50 | 25/25 | 69 ± 10 | 133 ± 110 | 102–164 | 0.62 (0.51–0.73) | 0.55 (0.43–0.67) |
VaD | 22 | 8/14 | 72 ± 10** | 140 ± 150 | 73–206 | 0.56 (0.40–0.72) | 0.51 (0.34–0.68) |
FTD | 17 | 11/6 | 68 ± 12 | 125 ± 108 | 69–181 | 0.65 (0.50–0.80) | 0.55 (0.38–0.73) |
CJD | 78 | 51/27 | 67 ± 8 | 189 ± 167 | 151–227 | 0.81 (0.74–0.88) | 0.72 (0.63–0.81) |
LBD | 34 | 13/21 | 69 ± 8 | 167 ± 157 | 112–222 | 0.70 (0.59–0.81) | 0.63 (0.49–0.76) |